Meeting
2022 ASCO Gastrointestinal Cancers Symposium
The influence of major hepatectomy on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subset analysis of JCOG1113.
Authors
Tatsuya Okuno
Department of Medical Oncology, Kindai University, Faculty of Medicine, Osakasayama City, Osaka, Japan
Tatsuya Okuno , Chigusa Morizane , Takuji Okusaka , Junki Mizusawa , Tomoko Kataoka , Masafumi Ikeda , Masato Ozaka , Kazuya Sugimori , Akiko Todaka , Satoshi Shimizu , Nobumasa Mizuno , Mitsugu Sekimoto , Keiji Sano , Kazutoshi Tobimatsu , Akio Katanuma , Kunihito Gotoh , Hironori Yamaguchi , Hiroshi Ishii , Makoto Ueno , Junji Furuse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.419
Abstract #
419
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113.
First Author: Makoto Ueno
Poster
2017 Gastrointestinal Cancers Symposium
Frequency of severe neutropenia occurring as an adverse events of gemcitabine plus cisplatin chemotherapy in patients with recurrent biliary tract cancer compared to those with unresectable biliary tract cancer.
First Author: Noriko Fujishiro
Poster
2021 Gastrointestinal Cancers Symposium
Analysis of early tumor shrinkage and depth of response in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin or gemcitabine plus S-1: An exploratory analysis of JCOG1113.
First Author: Naohiro Okano
Poster
2018 ASCO Annual Meeting
Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT).
First Author: Makoto Ueno